C WorldWide Group Holding A S Raises Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

C WorldWide Group Holding A S grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,307,035 shares of the biopharmaceutical company’s stock after acquiring an additional 58,216 shares during the quarter. Gilead Sciences accounts for 5.0% of C WorldWide Group Holding A S’s portfolio, making the stock its 8th largest holding. C WorldWide Group Holding A S owned approximately 0.33% of Gilead Sciences worth $348,956,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Sanders Capital LLC acquired a new stake in shares of Gilead Sciences in the third quarter valued at $427,585,000. Renaissance Technologies LLC increased its stake in shares of Gilead Sciences by 35.0% in the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock valued at $736,667,000 after buying an additional 2,700,600 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after buying an additional 2,148,697 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Gilead Sciences by 50.0% in the second quarter. The Manufacturers Life Insurance Company now owns 6,191,622 shares of the biopharmaceutical company’s stock valued at $438,244,000 after buying an additional 2,062,886 shares in the last quarter. Finally, BlackRock Inc. boosted its holdings in Gilead Sciences by 1.9% in the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after acquiring an additional 1,937,031 shares during the last quarter. 76.11% of the stock is owned by institutional investors.

Several equities analysts recently issued reports on GILD shares. William Blair reiterated a “buy” rating on shares of Gilead Sciences in a report on Thursday, October 19th. Berenberg Bank set a $96.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, October 25th. Mizuho set a $77.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Sunday, October 29th. Finally, Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and raised their price target for the company from $73.67 to $94.00 in a report on Thursday, November 30th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eighteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $85.58.

In related news, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.64, for a total value of $1,119,600.00. Following the sale, the executive vice president now owns 70,988 shares of the company’s stock, valued at approximately $5,298,544.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.98, for a total value of $5,498,508.34. Following the transaction, the insider now directly owns 3,070,099 shares in the company, valued at approximately $230,196,023.02. The disclosure for this sale can be found here. Insiders have sold a total of 503,333 shares of company stock worth $37,834,758 in the last quarter. 1.30% of the stock is currently owned by company insiders.

Gilead Sciences, Inc. (GILD) traded down $1.76 during trading hours on Friday, hitting $81.73. The stock had a trading volume of 8,838,208 shares, compared to its average volume of 8,410,000. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $89.54. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The company has a market cap of $104,480.00, a PE ratio of 9.30, a PEG ratio of -1.84 and a beta of 1.22.

TRADEMARK VIOLATION NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/03/c-worldwide-group-holding-a-s-purchases-58216-shares-of-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply